SCHEMBL1775528

SCHEMBL1775528

COc1ccc(C(OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2O)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TYMS P04818 1/20 0.56
POLB P06746 1/20 0.53
TYMP P19971 1/20 0.53
TK1 P04183 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2460809 1.00 TYMS (0.56) TYMSPOLBTYMPTK1
SCHEMBL9015743 1.00 TYMS (0.56) TYMSPOLBTYMPTK1
SCHEMBL14064188 1.00 TYMS (0.56) TYMSPOLBTYMPTK1
SCHEMBL22983972 1.00 TYMS (0.56) TYMSPOLBTYMPTK1
SCHEMBL2460807 1.00 TYMS (0.56) TYMSPOLBTYMPTK1
SCHEMBL22984023 1.00 TYMS (0.56) TYMSPOLBTYMPTK1
SCHEMBL22983968 1.00 TYMS (0.56) TYMSPOLBTYMPTK1
SCHEMBL23517951 1.00 TYMS (0.56) TYMSPOLBTYMPTK1
SCHEMBL7535874 1.00 TYMS (0.56) TYMSPOLBTYMPTK1
SCHEMBL6250998 1.00 TYMS (0.56) TYMSPOLBTYMPTK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6894158-B2 Methods of producing phosphitylated compounds HONEYWELL INTERNATIONAL INC. (US) 2005-05-17 US claimed
EP-1476407-A2 METHODS OF PRODUCING PHOSPHITYLATED COMPOUNDS Honeywell International Inc. (US) 2004-11-17 EP claimed
US-20030232980-A1 Methods of producing phosphitylated compounds HONEYWELL INTERNATIONAL INC. 2003-12-18 US claimed
WO-2003072586-A2 METHODS OF PRODUCING PHOSPHITYLATED COMPOUNDS HONEYWELL INTERNATIONAL INC. (US) 2003-09-04 WO claimed
EP-4748941-A2 NUCLEOSIDES AND NUCLEOTIDES WITH 3 -HYDROXY BLOCKING GROUPS Illumina Cambridge Limited (GB) 2026-05-27 EP disclosed
US-20260138999-A1 REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS BRISTOL MYERS SQUIBB CO (US) 2026-05-21 US disclosed
EP-4741411-A2 OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE AJINOMOTO CO., INC. (JP) 2026-05-13 EP disclosed
US-20260125413-A1 UNIVERSAL SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS AM CHEMICALS LLC (US) 2026-05-07 US disclosed
EP-3221330-B1 PHOSPHORAMIDITE SYNTHONES FOR THE SYNTHESIS OF SELF-NEUTRALIZING OLIGONUCLEOTIDE COMPOUNDS ZATA PHARMACEUTICALS INC (US) 2026-04-22 EP disclosed
EP-3902814-B1 NUCLEOSIDES AND NUCLEOTIDES WITH 3'-HYDROXY BLOCKING GROUPS AND THEIR USE IN POLYNUCLEOTIDE SEQUENCING METHODS ILLUMINA CAMBRIDGE LTD (GB) 2026-04-08 EP disclosed
EP-4320138-B1 PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES BACHEM AG (CH) 2026-04-01 EP disclosed
US-12559517-B2 Oligonucleotide manufacturing method AJINOMOTO CO., INC. (JP) 2026-02-24 US disclosed
EP-0406309-A1 OLIGONUCLEOTIDE N-ALKYLPHOSPHORAMIDATES THE UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) 1991-01-09 EP disclosed
WO-1989009221-A1 OLIGONUCLEOTIDE N-ALKYLPHOSPHORAMIDATES UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) 1989-10-05 WO disclosed
US-4835263-A Novel compounds containing an oligonucleotide sequence bonded to an intercalating agent, a process for their synthesis and their use CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1989-05-30 US disclosed
EP-0290583-A1 -g(a) OLIGONUCLEOTIDES. CENTRE NAT RECH SCIENT (FR) 1988-11-17 EP disclosed
WO-1988004301-A1 alpha OLIGONUCLEOTIDES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 1988-06-16 WO disclosed
EP-0117777-B1 COMPOUNDS CONTAINING AN OLIGONUCLEOTIDE BONDED TO AN INTERCALLATING AGENT, A PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1987-12-23 EP disclosed
EP-0119621-A1 Interleukin-2 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1984-09-26 EP disclosed
EP-0117777-A1 Compounds containing an oligonucleotide bonded to an intercallating agent, a process for their preparation and their application Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1984-09-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138999-A1 REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS RNGTT, CDA, DCTD TYMS 387/4885POLB 30/4885TYMP 80/4885
US-12559517-B2 Oligonucleotide manufacturing method POLL, IGF2BP1, POLI TYMS 363/4885POLB 25/4885TYMP 149/4885
US-20260125413-A1 UNIVERSAL SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS SSU72, NSUN2, POLR2H TYMS 448/4885POLB 9/4885TYMP 212/4885
US-20030232980-A1 Methods of producing phosphitylated compounds PHOSPHO1, INPPL1, PLCG1 TYMS 2121/4885POLB 2116/4885TYMP 678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.